Skip to main navigation

Home
About
- Our Leadership
Our Science
Clinical Trials
Careers
Investors
Contact

Press Releases

Year

Aug 24 / 26

Belite Bio to Host Virtual Commercial Day on September 2, 2026

Aug 21 / 26

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Aug 12 / 26

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

Aug 11 / 26

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

Aug 06 / 26

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

Jul 20 / 26

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

Jul 15 / 26

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Jul 06 / 26

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Jul 06 / 26

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 9 of 24

Belite Bio^® Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA